AMO Pharma in Collaboration with Population Health Research Institute (PHRI) and Venca Research Inc. Announces FDA Advice on Potential Phase 3 Development Path for AMO-02 in Treatment of Arrhythmogenic Cardiomyopathy (ACM)

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

AMO-Pharma-Limited

More Like This

PR Newswire associated0

AMO Pharma Enters into License Agreement with Population Health Research Institute (PHRI) and Venca Research Inc. to Advance Largest-Ever Study in Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

PR Newswire associated0

AMO Pharma Announces Collaboration with Population Health Research Institute to Advance Proof of Concept Clinical Trial to Assess Efficacy of Tideglusib in Treatment of Arrhythmogenic Cardiomyopathy

AMO Pharma Announces Update on Scientific Advice for Registrational Clinical Study of AMO-02 in Congenital Myotonic Dystrophy Type 1 Following Meetings with the U.S. Food and Drug Administration, the U.K. Medicines and Healthcare products Regulatory Agency and Health Canada

PR Newswire associated0

AMO Pharma Reports Long-Term Safety Data from REACHCDM-X Study of AMO-02 in Treatment of Congenital Myotonic Dystrophy Type 1

PR Newswire associated0

AMO Pharma Completes Meeting with U.S. FDA and Outlines Plans to Advance Clinical Development of AMO-02 (tideglusib) in Treatment of Myotonic Dystrophy

PR Newswire associated0

AMO Pharma Announces Preclinical Data Showing AMO-02 Improves Muscle Function, Glucose Handling and CNS function in Mouse Models of Duchenne Muscular Dystrophy

Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA

CorFlow Therapeutics Announces FDA Approval of the MOCA-II IDE Pivotal Trial to Validate a Novel Heart Attack Care Technology